SedentaryNCT07550829
Effects of CE on the Risk of Arteriosclerosis in SED Postmenopausal Women
A study testing AE group, RE group and CE group in people with Sedentary, run by Beijing Sport University at 1 site in China.
Trial summary
This study investigated the effects of three exercise modalities: aerobic exercise, resistance exercise, and combined exercise on the risk of arteriosclerosis in sedentary postmenopausal women. Read more about this study
- Who is it for?
- Ages 45 to 69 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Sedentary
- What is being tested?
- AE group, RE group and CE group
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 113 participants
- Where
- 1 siteChina
- Study dates
- 15 Feb 2025to 30 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 69 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participants have been postmenopausal for more than 12 months and have not received any exogenous estrogen supplementation after menopause.
- Participants were screened using the International Physical Activity Questionnaire-Short Form (IPAQ-S), with a physical activity level classified as "low." They must not have engaged in moderate-intensity physical activity for at least 3 days per week, with a duration of no less than 30 minutes per day, for over 3 consecutive months.
- Participants were screened using the Physical Activity Readiness Questionnaire+ (PAR-Q+) and be deemed safe to undergo further intervention.
Who cannot join
- Participants with acute or chronic musculoskeletal disorders, cardiovascular diseases, or similar conditions.
- Participants with abnormal blood pressure: resting systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg, or those taking antihypertensive medications.
- Participants with abnormally high arterial stiffness (within pathological range): brachial-ankle pulse wave velocity (baPWV) >1800 cm/s.
- Participants recently taken medications that may affect blood indicators, such as hormones or anti-inflammatory drugs.
- Participants with unstable body weight in the past 3 months (fluctuation greater than ±2.5 kg).
- Participants currently participating in other intervention studies or those with regular exercise habits in daily life.
- Participants who smoke or consume alcohol regularly.
Trial locations and contacts
1 site in 1 country.
China1 site
School of Sports Medicine and Rehabilitation, Beijing Sport University
Beijing
About this study
Official title: Effects of Combined Exercise on the Risk of Arteriosclerosis in Sedentary Postmenopausal Women
This study investigated the effects of three exercise modalities: aerobic exercise, resistance exercise, and combined exercise on the risk of arteriosclerosis in sedentary postmenopausal women.
Read the detailed description
This study aims to compare the effects of different kinds of exercise on the risk of arteriosclerosis in sedentary postmenopausal women. Participants were recruited and randomly assigned to aerobic exercise, resistance exercise, combined exercise or control group. The intervention lasted for 12 weeks. Endothelial function indicators, chronic inflammation indicators, arteriosclerosis related indicators, blood pressure indicators were assessed before and after the intervention.
- Conditions
- Sedentary
- Being tested
- AE group, RE group, CE group, ON group
- Keywords
- Combined exercise, Arteriosclerosis, Sedentary, Postmenopausal women
- Medical subject headings
- Sedentary Behavior, Arteriosclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AE groupBehavioural
Aerobic exercise
RE groupBehavioural
Resistance exercise
CE groupBehavioural
Combined exercise
ON groupBehavioural
No intervention
| Study group | Role | What they receive |
|---|---|---|
| AE group | Active comparator | Not described Receives: Behavioral: AE group |
| RE group | Active comparator | Not described Receives: Behavioral: RE group |
| CE group | Active comparator | Not described Receives: Behavioral: CE group |
| CON group | Active comparator | Not described Receives: Behavioral: ON group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Flow mediated dilation (FMD)
The change of flow mediated dilation before and after intervention.
Measured: 12 weeks
Brachial ankle pulse wave velocity (baPWV)
The change of baPWV before and after intervention.
Measured: 12 weeks
Ankle brachial index (ABI)
The change of ABI before and after intervention.
Measured: 12 weeks
Carotid intima-media thickness (cIMT)
The change of cIMT before and after intervention.
Measured: 12 weeks
Systolic blood pressure (SBP)
The change of SBP before and after intervention.
Measured: 12 weeks
Diastolic blood pressure (DBP)
The change of DBP before and after intervention.
Measured: 12 weeks
Peak systolic velocity (PSV)
The change of PSV of carotid artery before and after intervention.
Measured: 12 weeks
End diastolic velocity (EDV)
The change of EDV of carotid artery before and after intervention.
Measured: 12 weeks
Pulsatility index (PI)
The change of PI of carotid artery before and after intervention.
Measured: 12 weeks
Resistance index (RI)
The change of RI of carotid artery before and after intervention.
Measured: 12 weeks
Wall Shear Stress (WSS)
The change of WSS of carotid artery before and after intervention.
Measured: 12 weeks
Secondary outcomes (30)
Nitric oxide (NO)
The change of serum NO before and after intervention.
Measured: 12 weeks
Prostacyclin (PGI2)
The change of serum PGI2 before and after intervention.
Measured: 12 weeks
Endothelin-1 (ET-1)
The change of serum ET-1 before and after intervention.
Measured: 12 weeks
Angiotensin II (AngII)
The change of serum AngII before and after intervention.
Measured: 12 weeks
C-Reactive protein (CRP)
The change of serum CRP before and after intervention.
Measured: 12 weeks
Interleukin-6 (IL-6)
The change of serum IL-6 before and after intervention.
Measured: 12 weeks
Estrogen
The change of serum estrogen before and after intervention.
Measured: 12 weeks
Soluble intercellular adhesion molecule-1(sICAM-1)
The change of serum sICAM-1 before and after intervention.
Measured: 12 weeks
Soluble vascular cell adhesion molecule-1 (sVCAM-1)
The change of serum sVCAM-1 before and after intervention.
Measured: 12 weeks
Total Cholesterol (TC)
The change of serum TC before and after intervention.
Measured: 12 weeks
High-density lipoprotein cholesterol (HDL-C)
The change of serum HDL-C before and after intervention.
Measured: 12 weeks
Low-density lipoprotein cholesterol (LDL-C)
The change of serum LDL-C before and after intervention.
Measured: 12 weeks
Left ventricular posterior wall thickness at end-diastole (LVPWd)
The change of LVPWd before and after intervention.
Measured: 12 weeks
Left ventricular posterior wall thickness at end-systole (LVPWs)
The change of LVPWs before and after intervention.
Measured: 12 weeks
Stroke volume (SV)
The change of SV before and after intervention.
Measured: 12 weeks
Heart rate (HR)
The change of HR before and after intervention.
Measured: 12 weeks
Left ventricular ejection fraction (LVEF)
The change of LVEF before and after intervention.
Measured: 12 weeks
Cardiac output (CO)
The change of CO before and after intervention.
Measured: 12 weeks
Endothelial Nitric Oxide Synthase (eNOS)
The change of serum eNOS before and after intervention.
Measured: 12 weeks
Maximal oxygen uptake (VO2max)
The change of VO2max before and after intervention.
Measured: 12 weeks
Body mass index (BMI)
The change of BMI before and after intervention.
Measured: 12 weeks
Body fat weight
The change of body fat weight before and after intervention.
Measured: 12 weeks
Body fat%
The change of body fat% before and after intervention.
Measured: 12 weeks
Pittsburgh sleep quality index (PSQI)
The change of PSQI before and after intervention.
Measured: 12 weeks
Food frequency questionnaire (FFQ)
The change of FFQ before and after intervention.
Measured: 12 weeks
Cluster of Differentiation 14 (CD14) mRNA and Protein Expression
The change of CD14 mRNA and Protein Expression before and after intervention.
Measured: 12 weeks
Mitogen-activated protein kinase 14 (MAPK14) mRNA
The change of MAPK14 mRNA before and after intervention.
Measured: 12 weeks
p38 Mitogen-activated protein kinase (p38 MAPK) Protein Expression
The change of p38 MAPK Protein Expression before and after intervention.
Measured: 12 weeks
Tetraspanin 4 (TSPAN4) mRNA and Protein Expression
The change of TSPAN4 mRNA and Protein Expression before and after intervention.
Measured: 12 weeks
Nitric Oxide Synthase 3 (NOS3) mRNA and Protein Expression
The change of NOS3 mRNA and Protein Expression before and after intervention.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2026
- Study start15 Feb 2025
- Primary completion30 Jul 2025
- Study completion30 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SedentaryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 113 participants (actual)
Sponsor and investigators
- Lead sponsor
- Beijing Sport University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07550829
- Sponsor's protocol ID
- EOCEOTROAISPW
- Status last verified
- May 2025
- First submitted
- 20 Apr 2026
- Last updated
- 24 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Combined Exercise on the Risk of Arteriosclerosis in Sedentary Postmenopausal Women
- ClinicalTrials.gov ID
- NCT07550829
- Acronym / sponsor ID
- EOCEOTROAISPW
- Conditions
- Sedentary
- Keywords
- Combined exercise, Arteriosclerosis, Sedentary, Postmenopausal women
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 113 participants (actual)
- Lead sponsor
- Beijing Sport UniversityUniversity, hospital or other
- Study start
- 15 Feb 2025 (actual)
- Primary completion
- 30 Jul 2025 (actual)
- Study completion
- 30 Dec 2025 (actual)
- First posted
- 24 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study investigated the effects of three exercise modalities: aerobic exercise, resistance exercise, and combined exercise on the risk of arteriosclerosis in sedentary postmenopausal women.
Detailed description
This study aims to compare the effects of different kinds of exercise on the risk of arteriosclerosis in sedentary postmenopausal women. Participants were recruited and randomly assigned to aerobic exercise, resistance exercise, combined exercise or control group. The intervention lasted for 12 weeks. Endothelial function indicators, chronic inflammation indicators, arteriosclerosis related indicators, blood pressure indicators were assessed before and after the intervention.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| AE group | Active comparator | Behavioral: AE group |
| RE group | Active comparator | Behavioral: RE group |
| CE group | Active comparator | Behavioral: CE group |
| CON group | Active comparator | Behavioral: ON group |
Who may qualify
- Ages
- 45 to 69 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Participants have been postmenopausal for more than 12 months and have not received any exogenous estrogen supplementation after menopause.
- Participants were screened using the International Physical Activity Questionnaire-Short Form (IPAQ-S), with a physical activity level classified as "low." They must not have engaged in moderate-intensity physical activity for at least 3 days per week, with a duration of no less than 30 minutes per day, for over 3 consecutive months.
- Participants were screened using the Physical Activity Readiness Questionnaire+ (PAR-Q+) and be deemed safe to undergo further intervention.
Key exclusion criteria (7 listed)
- Participants with acute or chronic musculoskeletal disorders, cardiovascular diseases, or similar conditions.
- Participants with abnormal blood pressure: resting systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg, or those taking antihypertensive medications.
- Participants with abnormally high arterial stiffness (within pathological range): brachial-ankle pulse wave velocity (baPWV) >1800 cm/s.
- Participants recently taken medications that may affect blood indicators, such as hormones or anti-inflammatory drugs.
- Participants with unstable body weight in the past 3 months (fluctuation greater than ±2.5 kg).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AE groupAerobic exercise | Behavioural | AE group |
| RE groupResistance exercise | Behavioural | RE group |
| CE groupCombined exercise | Behavioural | CE group |
| ON groupNo intervention | Behavioural | CON group |
Primary outcome
Flow mediated dilation (FMD)
Time frame: 12 weeks
The change of flow mediated dilation before and after intervention.
Brachial ankle pulse wave velocity (baPWV)
Time frame: 12 weeks
The change of baPWV before and after intervention.
Ankle brachial index (ABI)
Time frame: 12 weeks
The change of ABI before and after intervention.
Carotid intima-media thickness (cIMT)
Time frame: 12 weeks
The change of cIMT before and after intervention.
Systolic blood pressure (SBP)
Time frame: 12 weeks
The change of SBP before and after intervention.
Diastolic blood pressure (DBP)
Time frame: 12 weeks
The change of DBP before and after intervention.
Peak systolic velocity (PSV)
Time frame: 12 weeks
The change of PSV of carotid artery before and after intervention.
End diastolic velocity (EDV)
Time frame: 12 weeks
The change of EDV of carotid artery before and after intervention.
Pulsatility index (PI)
Time frame: 12 weeks
The change of PI of carotid artery before and after intervention.
Resistance index (RI)
Time frame: 12 weeks
The change of RI of carotid artery before and after intervention.
Wall Shear Stress (WSS)
Time frame: 12 weeks
The change of WSS of carotid artery before and after intervention.
30 secondary outcomes
Nitric oxide (NO)
Time frame: 12 weeks
Prostacyclin (PGI2)
Time frame: 12 weeks
Endothelin-1 (ET-1)
Time frame: 12 weeks
Angiotensin II (AngII)
Time frame: 12 weeks
C-Reactive protein (CRP)
Time frame: 12 weeks
Interleukin-6 (IL-6)
Time frame: 12 weeks
Estrogen
Time frame: 12 weeks
Soluble intercellular adhesion molecule-1(sICAM-1)
Time frame: 12 weeks
Soluble vascular cell adhesion molecule-1 (sVCAM-1)
Time frame: 12 weeks
Total Cholesterol (TC)
Time frame: 12 weeks
High-density lipoprotein cholesterol (HDL-C)
Time frame: 12 weeks
Low-density lipoprotein cholesterol (LDL-C)
Time frame: 12 weeks
Left ventricular posterior wall thickness at end-diastole (LVPWd)
Time frame: 12 weeks
Left ventricular posterior wall thickness at end-systole (LVPWs)
Time frame: 12 weeks
Stroke volume (SV)
Time frame: 12 weeks
Heart rate (HR)
Time frame: 12 weeks
Left ventricular ejection fraction (LVEF)
Time frame: 12 weeks
Cardiac output (CO)
Time frame: 12 weeks
Endothelial Nitric Oxide Synthase (eNOS)
Time frame: 12 weeks
Maximal oxygen uptake (VO2max)
Time frame: 12 weeks
Body mass index (BMI)
Time frame: 12 weeks
Body fat weight
Time frame: 12 weeks
Body fat%
Time frame: 12 weeks
Pittsburgh sleep quality index (PSQI)
Time frame: 12 weeks
Food frequency questionnaire (FFQ)
Time frame: 12 weeks
Cluster of Differentiation 14 (CD14) mRNA and Protein Expression
Time frame: 12 weeks
Mitogen-activated protein kinase 14 (MAPK14) mRNA
Time frame: 12 weeks
p38 Mitogen-activated protein kinase (p38 MAPK) Protein Expression
Time frame: 12 weeks
Tetraspanin 4 (TSPAN4) mRNA and Protein Expression
Time frame: 12 weeks
Nitric Oxide Synthase 3 (NOS3) mRNA and Protein Expression
Time frame: 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
Related trials for Sedentary
Active, not recruiting
A Pilot Factorial Trial of an Integrated Lifestyle Intervention
Physical Inactivity, Overweight and Obesity
Recruiting
Yoga vs. Stretching-Strengthening: Physical Fitness in Sedentary Young Adults
Sedentary Lifestlye, Exercise
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Recruiting
Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors
Obesity, Smoking Cessation
Not yet recruiting
Be Well at Work-Plus: A Depression and Physical Activity Intervention for Hospital Service Workers (Aim 3)
Depression, Physical Inactivity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AE group, RE group and CE group in people with Sedentary, run by Beijing Sport University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Flow mediated dilation (FMD) (time frame: 12 weeks). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.